NO2820009T3 - - Google Patents

Info

Publication number
NO2820009T3
NO2820009T3 NO13710222A NO13710222A NO2820009T3 NO 2820009 T3 NO2820009 T3 NO 2820009T3 NO 13710222 A NO13710222 A NO 13710222A NO 13710222 A NO13710222 A NO 13710222A NO 2820009 T3 NO2820009 T3 NO 2820009T3
Authority
NO
Norway
Application number
NO13710222A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47296498&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2820009(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2820009T3 publication Critical patent/NO2820009T3/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/48Separation; Purification; Stabilisation; Use of additives
    • C07C67/62Use of additives, e.g. for stabilisation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/08Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/28Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/297Preparation of carboxylic acid esters by modifying the hydroxylic moiety of the ester, such modification not being an introduction of an ester group by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/48Separation; Purification; Stabilisation; Use of additives
    • C07C67/52Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/593Dicarboxylic acid esters having only one carbon-to-carbon double bond
    • C07C69/60Maleic acid esters; Fumaric acid esters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C07C69/604Polycarboxylic acid esters, the acid moiety containing more than two carboxyl groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NO13710222A 2011-06-08 2013-03-01 NO2820009T3 (sl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161494775P 2011-06-08 2011-06-08

Publications (1)

Publication Number Publication Date
NO2820009T3 true NO2820009T3 (sl) 2018-06-30

Family

ID=47296498

Family Applications (1)

Application Number Title Priority Date Filing Date
NO13710222A NO2820009T3 (sl) 2011-06-08 2013-03-01

Country Status (30)

Country Link
US (1) US9422226B2 (sl)
EP (1) EP2718257B1 (sl)
JP (3) JP6385273B6 (sl)
KR (2) KR20150080037A (sl)
CN (1) CN103649041A (sl)
AU (1) AU2012267524A1 (sl)
BR (1) BR112013031616A2 (sl)
CA (1) CA2838271A1 (sl)
CL (1) CL2013003483A1 (sl)
CO (1) CO6821956A2 (sl)
CY (1) CY1119920T1 (sl)
DK (1) DK2718257T3 (sl)
EA (1) EA201391638A1 (sl)
EC (1) ECSP14013123A (sl)
ES (1) ES2659771T3 (sl)
HR (1) HRP20180203T1 (sl)
HU (1) HUE036085T2 (sl)
IL (1) IL229656A0 (sl)
LT (1) LT2718257T (sl)
ME (1) ME02960B (sl)
MX (1) MX355421B (sl)
NO (1) NO2820009T3 (sl)
NZ (1) NZ618178A (sl)
PE (1) PE20141639A1 (sl)
PL (1) PL2718257T3 (sl)
PT (1) PT2718257T (sl)
RS (1) RS56972B1 (sl)
SG (1) SG195227A1 (sl)
SI (1) SI2718257T1 (sl)
WO (1) WO2012170923A1 (sl)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0410805A (pt) 2003-09-09 2006-06-27 Fumapharm Ag uso de derivados do ácido fumárico para tratamento da insuficiência cardìaca e asma
DE14172398T1 (de) 2004-10-08 2015-01-08 Forward Pharma A/S Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester
PL2334378T3 (pl) 2008-08-19 2014-09-30 Xenoport Inc Proleki wodorofumaranu metylu, ich kompozycje farmaceutyczne i sposoby zastosowania
PL2718257T3 (pl) 2011-06-08 2018-04-30 Biogen Ma Inc. Sposób przygotowywania dimetylofumaranu krystalicznego o wysokiej czystości
US10945984B2 (en) 2012-08-22 2021-03-16 Arbor Pharmaceuticals, Llc Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
US20140056973A1 (en) 2012-08-22 2014-02-27 Xenoport, Inc. Oral Dosage Forms Having a High Loading of a Methyl Hydrogen Fumarate Prodrug
US20140179779A1 (en) 2012-12-21 2014-06-26 Biogen Idec Ma Inc. Deuterium Substituted Fumarate Derivatives
EP3366668B1 (en) 2013-03-14 2023-06-21 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various deseases
US8669281B1 (en) 2013-03-14 2014-03-11 Alkermes Pharma Ireland Limited Prodrugs of fumarates and their use in treating various diseases
US10179118B2 (en) 2013-03-24 2019-01-15 Arbor Pharmaceuticals, Llc Pharmaceutical compositions of dimethyl fumarate
CN104098471A (zh) * 2013-04-03 2014-10-15 南京卡文迪许生物工程技术有限公司 富马酸二甲酯多晶型物及其制备方法和药物组合物
WO2014197860A1 (en) 2013-06-07 2014-12-11 Xenoport, Inc. Method of making monomethyl fumarate
US9421182B2 (en) 2013-06-21 2016-08-23 Xenoport, Inc. Cocrystals of dimethyl fumarate
JP2016534133A (ja) 2013-09-06 2016-11-04 ゼノポート,インコーポレイティド (n,n−ジエチルカルバモイル)メチル メチル(2e)ブト−2−エン−1,4−ジオエートの結晶形態、その合成方法及び使用
IN2013MU03070A (sl) * 2013-09-25 2015-07-17 Glenmark Pharmaceuticals Ltd
IN2014CH00308A (sl) * 2014-01-24 2015-07-31 Shilpa Medicare Ltd
EP3110793B1 (en) 2014-02-24 2019-08-21 Alkermes Pharma Ireland Limited Sulfonamide and sulfinamide prodrugs of fumarates and their use in treating various diseases
AU2015222880B2 (en) 2014-02-28 2016-11-24 Banner Life Sciences Llc Controlled release enteric soft capsules of fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
US10626076B2 (en) * 2014-03-17 2020-04-21 Biophore India Pharmaeuticals Pvt. Ltd. Process for the synthesis of dimethyl fumarate
US9999672B2 (en) 2014-03-24 2018-06-19 Xenoport, Inc. Pharmaceutical compositions of fumaric acid esters
WO2016001093A1 (en) * 2014-07-03 2016-01-07 Synthon B.V. Process for making microcrystalline dimethyl fumarate
CN104151165B (zh) * 2014-08-11 2016-08-24 广东东阳光药业有限公司 制备富马酸二甲酯的方法
CN104761453A (zh) * 2015-04-22 2015-07-08 河南中帅医药科技股份有限公司 一种富马酸二甲酯晶型及其制备方法
CA2987895A1 (en) * 2015-06-01 2016-12-08 Sun Pharmaceutical Industries Ltd. Pharmaceutical compositions of dimethyl fumarate
AU2016279997B2 (en) * 2015-06-17 2021-10-21 Biogen Ma Inc. Dimethyl fumarate particles and pharmaceutical compositions thereof
CN106316841A (zh) * 2015-06-30 2017-01-11 深圳翰宇药业股份有限公司 一种富马酸二甲酯的制备方法
WO2017013672A1 (en) * 2015-07-23 2017-01-26 Natco Pharma Ltd Process for the preparation of pharmaceutical grade dimethyl fumarate
US10011663B2 (en) 2016-02-04 2018-07-03 Eastman Chemical Company Vulcanizing composition containing cyclododecasulfur and improved cyclododecasulfur compound
RU2616605C1 (ru) * 2016-04-07 2017-04-18 Олег Ростиславович Михайлов Кристаллическая бета - модификация (Е)-диметилбутендиоата, способ её получения и фармацевтическая композиция на её основе
CN107285320A (zh) * 2017-08-02 2017-10-24 内蒙古新福地科技有限公司 一种氟硅酸钠的结晶方法及装置
KR102424621B1 (ko) * 2017-10-10 2022-07-25 화이자 인코포레이티드 로라티닙 유리 염기 수화물의 결정질 형태
WO2021142062A1 (en) 2020-01-10 2021-07-15 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
KR102271575B1 (ko) * 2020-09-16 2021-07-01 김갑용 염의 이온교환법을 이용한 친환경 고효율 에스터화반응 기반의 에스터화합물 제조방법 및 이의 화합물
JP6865489B1 (ja) * 2020-10-20 2021-04-28 株式会社エス・ディー・エス バイオテック 2,3,5,6−テトラクロロ−1,4−ベンゼンジカルボン酸ジメチルの製造方法

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1848724A (en) * 1932-03-08 Alphons
US2764609A (en) * 1953-07-24 1956-09-25 Monsanto Chemicals Isomerization of dialkyl maleates to dialkyl fumarates
US3078302A (en) * 1958-09-25 1963-02-19 Monsanto Chemicals Production of dialkyl fumarates
US3993684A (en) 1971-08-20 1976-11-23 Western Litho Plate & Supply Co. Monomeric compounds
US4866187A (en) 1976-09-24 1989-09-12 Exxon Research & Engineering Company Thio-bis(alkyl lactone acid esters) and thio-bis-(hydrocarbyl diacid esters) are useful additives for lubricating compositions
US4568756A (en) 1976-09-24 1986-02-04 Exxon Research & Engineering Co. Thio-bis-(alkyl lactone acid esters) and thio-bis-(hydrocarbyl diacid esters) are useful additives for lubricating compositions
US5118835A (en) 1976-09-24 1992-06-02 Exxon Research & Engineering Co. Thio-bis(alkyl lactone acid esters) and thio-bis (Hydrocarbyl diacid esters) are usefull additives for lubricating compositions
US4965375A (en) 1976-09-24 1990-10-23 Exxon Research And Engineering Co. Thio-bis-(alkyl lactone acid esters) and thio-bis-(hydrocarbyl diacid esters) are useful additives for lubricating compositions
US4417062A (en) 1976-09-24 1983-11-22 Exxon Research & Engineering Co. Thio-bis-(alkyl lactone acid esters) and thio-bis-(hydrocarbyl diacid esters) are useful additives for lubricating compositions
US4239636A (en) 1978-10-23 1980-12-16 Exxon Research & Engineering Co. Thio-bis-(alkyl lactone acid esters) and thio-bis-(hydrocarbyl diacid esters) are useful additives for lubricating compositions
JPS60193946U (ja) 1984-03-01 1985-12-24 内山 茂夫 変色炎を有するろうそく
JPS60193946A (ja) * 1984-03-16 1985-10-02 Nippon Oil & Fats Co Ltd ジイソプロピルフマレ−トの製造法
US5149695A (en) 1985-01-15 1992-09-22 Speiser Peter P Fumaric acid derivatives, process for the production thereof and pharmaceutical compositions containing same
CH664150A5 (de) 1985-01-15 1988-02-15 Peter Paul Prof Dr Speiser Fumarsaeureprodrug, verfahren zu seiner herstellung und dieses enthaltende darreichungsformen.
JPS61246147A (ja) * 1985-04-22 1986-11-01 Nippon Shokubai Kagaku Kogyo Co Ltd マレイン酸ジアルキルエステルの精製方法
US4866139A (en) 1986-10-07 1989-09-12 Exxon Chemical Patents Inc. Lactone modified, esterified dispersant additives useful in oleaginous compositions
US4954277A (en) 1986-10-07 1990-09-04 Exxon Chemical Patents Inc. Lactone modified, esterified or aminated additives useful in oleaginous compositions and compositions containing same
US4866140A (en) 1986-10-07 1989-09-12 Exxon Chemical Patents Inc. Lactone modified adducts or reactants and oleaginous compositions containing same
US4954276A (en) 1986-10-07 1990-09-04 Exxon Chemical Patents Inc. Lactone modified adducts or reactants and oleaginous compositions containing same
US4906394A (en) 1986-10-07 1990-03-06 Exxon Chemical Patents Inc. Lactone modified mono-or dicarboxylic acid based adduct dispersant compositions
US5032320A (en) 1986-10-07 1991-07-16 Exxon Chemical Patents Inc. Lactone modified mono- or dicarboxylic acid based adduct dispersant compositions
US4963275A (en) 1986-10-07 1990-10-16 Exxon Chemical Patents Inc. Dispersant additives derived from lactone modified amido-amine adducts
DE3711155A1 (de) * 1987-04-02 1988-10-13 Bayer Ag Verfahren zur herstellung von maleinsaeuredimethylester
US4971711A (en) 1987-07-24 1990-11-20 Exxon Chemical Patents, Inc. Lactone-modified, mannich base dispersant additives useful in oleaginous compositions
US4820432A (en) 1987-07-24 1989-04-11 Exxon Chemical Patents Inc. Lactone-modified, Mannich base dispersant additives useful in oleaginous compositions
US5424332A (en) 1987-10-19 1995-06-13 Speiser; Peter P. Pharmaceutical composition and process for the production thereof
US4959389A (en) 1987-10-19 1990-09-25 Speiser Peter P Pharmaceutical preparation for the treatment of psoriatic arthritis
US4943382A (en) 1988-04-06 1990-07-24 Exxon Chemical Patents Inc. Lactone modified dispersant additives useful in oleaginous compositions
US5153352A (en) 1988-10-25 1992-10-06 Bristol-Myers Squibb Company Process for preparation of intermediates of carbocyclic nucleoside analogs
DK0608020T3 (da) 1993-01-21 1997-12-29 Akzo Nobel Nv Lufttørrende vandige polymerdispersioner
CN1103398A (zh) * 1993-11-30 1995-06-07 张治明 一种由顺酐生产富马酸二甲酯的工艺方法
US6100339A (en) 1994-11-21 2000-08-08 Asahi Kasei Kogyo Kabushiki Kaisha Curable resin and resin composition comprising the same
EP0923559A1 (en) 1996-06-24 1999-06-23 Cytec Technology Corp. Polymerizable urea/ureido functional monomers
US6239189B1 (en) 1997-04-01 2001-05-29 Henkel Corporation Radiation-polymerizable composition and printing inks containing same
DE19721099C2 (de) 1997-05-20 1999-12-02 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten
CA2265844C (en) 1997-07-11 2007-10-30 Showa Denko K.K. New ether compounds and process for producing the same
US6376702B1 (en) 1997-07-11 2002-04-23 Showa Denko K.K. Ether compound, production thereof and curable compositions
GB9724004D0 (en) 1997-11-13 1998-10-21 Kvaerner Process Tech Ltd Process
DE19814358C2 (de) 1998-03-31 2002-01-17 Fumapharm Ag Muri Verwendung von Alkylhydrogenfumaraten zur Behandlung von Psoriasis, psoriatischer Arthritis, Neurodermitis und Enteritis regionalis Crohn
DE19839566C2 (de) 1998-08-31 2002-01-17 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten in der Transplantationsmedizin
DE19848260C2 (de) 1998-10-20 2002-01-17 Fumapharm Ag Muri Fumarsäure-Mikrotabletten
DE19853487A1 (de) 1998-11-19 2000-05-25 Fumapharm Ag Muri Verwendung von Dialkylfumaraten
US7056965B2 (en) 1999-12-27 2006-06-06 Asahi Kasei Kabushiki Kaisha Polyoxymethylene resin composition
DE10000577A1 (de) 2000-01-10 2001-07-26 Fumapharm Ag Muri Verwendung von Fumarsäurederivaten zur Behandlung mitochondrialer Krankheiten
WO2001060780A1 (fr) 2000-02-15 2001-08-23 Showa Denko K.K. Procede de production d'ester fumarique
JP2001281800A (ja) 2000-03-31 2001-10-10 Konica Corp 熱現像写真感光材料
US6586452B1 (en) 2000-07-14 2003-07-01 Merck & Co., Inc. C1 to C4 side chain modified nodulisporic acid analogs
US20020098451A1 (en) 2000-09-07 2002-07-25 Tadashi Arimoto Photothermographic material
WO2002055063A2 (de) 2001-01-12 2002-07-18 Fumapharm Ag Fumarsäureamide
DE10101307A1 (de) 2001-01-12 2002-08-01 Fumapharm Ag Muri Fumarsäurederivate als NF-kappaB-Inhibitor
JP2003160535A (ja) * 2001-11-28 2003-06-03 Nof Corp 不飽和二塩基酸ジエステルの製造方法
EP2105431A1 (en) 2002-02-28 2009-09-30 Sumitomo Chemical Company, Limited Process for Producing Chromone Compound
DE10217314A1 (de) 2002-04-18 2003-11-13 Fumapharm Ag Muri Carbocyclische und Oxacarboncyclische Fumarsäure-Oligomere
JP2003315960A (ja) 2002-04-25 2003-11-06 Konica Minolta Holdings Inc 銀塩光熱写真ドライイメージング材料
JP4259815B2 (ja) * 2002-06-06 2009-04-30 ダイセル化学工業株式会社 高純度酢酸ブチルの製造方法
BRPI0410805A (pt) 2003-09-09 2006-06-27 Fumapharm Ag uso de derivados do ácido fumárico para tratamento da insuficiência cardìaca e asma
JP4163653B2 (ja) 2004-02-27 2008-10-08 株式会社日本触媒 光学部品用硬化性組成物
US7557241B2 (en) 2004-08-30 2009-07-07 Sanyo Chemical Industries, Ltd. Method for producing α,β-unsaturated carboxylic acid ester, α,β-unsaturated carboxylic acid ester, and lubricating oil additive
DE14172398T1 (de) 2004-10-08 2015-01-08 Forward Pharma A/S Gesteuerte Freisetzung von pharmazeutischen Zusammensetzungen mit Fumarinsäureester
TWI279403B (en) 2004-10-20 2007-04-21 Eternal Chemical Co Ltd Cyclobutanetetracarboxylate compound and preparation method thereof
EP1812374A1 (en) 2004-11-10 2007-08-01 Aditech Pharma AB Novel salts of fumaric acid monoalkylesters and their pharmaceutical use
MX2007007040A (es) 2004-12-17 2008-10-24 Metanomics Gmbh Proceso para el control de produccion de productos quimicos finos.
WO2006114900A1 (en) 2005-04-22 2006-11-02 Canon Kabushiki Kaisha Magnetic toner
DE102005022845A1 (de) 2005-05-18 2006-11-23 Fumapharm Ag Thiobernsteinsäurederivate und deren Verwendung
US20080227847A1 (en) 2005-07-07 2008-09-18 Aditech Pharma Ab Novel Salts of Fumaric Acid Monoalkylesters and Their Pharmaceutical Use
KR20080032098A (ko) 2005-08-12 2008-04-14 라이온 가부시키가이샤 나노 평활성과 에칭 내성을 가지는 포토레지스트 폴리머 및레지스트 조성물
EP1940382A2 (en) 2005-10-07 2008-07-09 Aditech Pharma AB Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
JP2009510137A (ja) 2005-10-07 2009-03-12 アディテック・ファルマ・アクチボラゲット フマル酸エステルを含む制御放出医薬組成物
CA2654325A1 (en) 2006-06-16 2007-12-21 Gumlink A/S Chewing gum comprising a hydrophobic enzyme formulation
PT2653873T (pt) 2007-02-08 2022-07-26 Biogen Ma Inc Composições e utilizações para o tratamento de esclerose múltipla
SI2139467T1 (sl) 2007-02-08 2017-01-31 Biogen Ma Inc. Zaščita živčevja pri demielinizacijskih obolenjih
WO2009045637A2 (en) 2007-08-10 2009-04-09 Genomatica, Inc. Methods for the synthesis of acrylic acid and derivatives from fumaric acid
US8729295B2 (en) 2007-10-26 2014-05-20 The Purolite Company Controlled catalysis
US8318893B2 (en) 2007-12-12 2012-11-27 Mitsubishi Chemical Corporation Aliphatic polyester resin and its production method
SI2564839T1 (sl) 2009-01-09 2016-09-30 Forward Pharma A/S Farmacevtska formulacija, obsegajoča enega ali več estrov fumarne kisline v erozijskem ogrodju
NZ595941A (en) 2009-04-29 2014-02-28 Biogen Idec Inc Treatment of neurodegeneration and neuroinflammation
EP2462103A4 (en) 2009-08-07 2014-01-08 Invista Tech Sarl HYDROGENATION AND ESTERIFICATION TO FORM DIESTERS
EP2533634B1 (en) 2010-02-12 2015-10-21 Biogen MA Inc. Neuroprotection in demyelinating diseases
CN102757346A (zh) 2011-04-26 2012-10-31 中国科学院兰州化学物理研究所 一种富马酸二甲酯的制备方法
KR20140036257A (ko) 2011-05-26 2014-03-25 바이오겐 아이덱 엠에이 인코포레이티드 다발성 경화증 치료 및 미엘린 함량 보존 및/또는 증가 방법
PL2718257T3 (pl) 2011-06-08 2018-04-30 Biogen Ma Inc. Sposób przygotowywania dimetylofumaranu krystalicznego o wysokiej czystości
CN102432464A (zh) 2011-12-14 2012-05-02 费近峰 一种富马酸二甲酯的连续生产工艺
KR102105217B1 (ko) 2012-02-07 2020-06-01 바이오젠 엠에이 인코포레이티드 다이메틸 푸마레이트를 함유하는 약학 조성물
CN102766050A (zh) 2012-08-10 2012-11-07 太仓市运通化工厂 一种富马酸二甲酯的合成方法
US20140179779A1 (en) 2012-12-21 2014-06-26 Biogen Idec Ma Inc. Deuterium Substituted Fumarate Derivatives
CN103848739A (zh) 2014-03-20 2014-06-11 徐晓宁 一种高纯度富马酸二甲酯的生产方法

Also Published As

Publication number Publication date
CL2013003483A1 (es) 2014-05-09
MX2013014320A (es) 2014-01-31
JP2016155868A (ja) 2016-09-01
US20140200363A1 (en) 2014-07-17
SG195227A1 (en) 2013-12-30
SI2718257T1 (sl) 2018-04-30
CO6821956A2 (es) 2013-12-31
ES2659771T3 (es) 2018-03-19
ECSP14013123A (es) 2014-06-30
NZ618178A (en) 2016-03-31
PL2718257T3 (pl) 2018-04-30
PE20141639A1 (es) 2014-11-08
EP2718257B1 (en) 2017-11-15
EP2718257A1 (en) 2014-04-16
ME02960B (me) 2018-07-20
HUE036085T2 (hu) 2018-06-28
LT2718257T (lt) 2018-03-12
MX355421B (es) 2018-04-18
CN103649041A (zh) 2014-03-19
JP6385273B2 (ja) 2018-09-05
HRP20180203T1 (hr) 2018-04-06
CY1119920T1 (el) 2018-06-27
US9422226B2 (en) 2016-08-23
AU2012267524A1 (en) 2013-12-12
JP2018162266A (ja) 2018-10-18
JP2014522413A (ja) 2014-09-04
WO2012170923A1 (en) 2012-12-13
IL229656A0 (en) 2014-01-30
CA2838271A1 (en) 2012-12-13
KR20150080037A (ko) 2015-07-08
EP2718257A4 (en) 2015-08-12
DK2718257T3 (en) 2018-02-12
PT2718257T (pt) 2018-02-26
KR20140035995A (ko) 2014-03-24
RS56972B1 (sr) 2018-05-31
JP6385273B6 (ja) 2023-12-15
EA201391638A1 (ru) 2014-05-30
BR112013031616A2 (pt) 2016-12-06

Similar Documents

Publication Publication Date Title
NO2820009T3 (sl)
BR112013022641A2 (sl)
AP3853A (sl)
BR112013031251A2 (sl)
BR112013027245A2 (sl)
BR112013024383A2 (sl)
BR112013026905A2 (sl)
BR112013023185A2 (sl)
BR112013022995A2 (sl)
BR112013026744A2 (sl)
BR112013017670A2 (sl)
BR112013027830A2 (sl)
BR112013023927A2 (sl)
BR112013024365A2 (sl)
BR112013028733A2 (sl)
BR112013027121A2 (sl)
BR112013027452A2 (sl)
BR112013031556A2 (sl)
BR112013024588A2 (sl)
BR112013026790A2 (sl)
BR112013032377A2 (sl)
BR112013032380A2 (sl)
BR112013032366A2 (sl)
BR112013026895A2 (sl)
BR112013018949A2 (sl)